Advanced Cell Technology (OTCBB: ACTC) announced that the second patient was dosed in the company’s Phase I/II trial for dry age-related macular degeneration using retinal pigment epithelial cells derived from human embryonic stem cells.
The patient is recovering uneventfully.
Daily Dose Conclusion: AMD is a big market and dry AMD is an un-met medical need. Should these patients start to have vision improvement the sky's the limit.
